429 related articles for article (PubMed ID: 17419952)
21. Targeting gene expression to tumor cells with loss of wild-type p53 function.
Zhu J; Gao B; Zhao J; Balmain A
Cancer Gene Ther; 2000 Jan; 7(1):4-12. PubMed ID: 10678350
[TBL] [Abstract][Full Text] [Related]
22. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
25. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
26. Restoration of the transcription activation function to mutant p53 in human cancer cells.
Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
[TBL] [Abstract][Full Text] [Related]
27. Structural and functional basis for therapeutic modulation of p53 signaling.
Bassett EA; Wang W; Rastinejad F; El-Deiry WS
Clin Cancer Res; 2008 Oct; 14(20):6376-86. PubMed ID: 18927276
[TBL] [Abstract][Full Text] [Related]
28. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
29. Human tumor suppressor p53 and DNA viruses.
Collot-Teixeira S; Bass J; Denis F; Ranger-Rogez S
Rev Med Virol; 2004; 14(5):301-19. PubMed ID: 15334538
[TBL] [Abstract][Full Text] [Related]
30. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.
Takimoto R; Wang W; Dicker DT; Rastinejad F; Lyssikatos J; el-Deiry WS
Cancer Biol Ther; 2002; 1(1):47-55. PubMed ID: 12174820
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53: the loaded gun.
Selivanova G
Curr Opin Investig Drugs; 2001 Aug; 2(8):1136-41. PubMed ID: 11892926
[TBL] [Abstract][Full Text] [Related]
32. P53 tumor suppressor gene therapy for cancer.
Nielsen LL; Maneval DC
Cancer Gene Ther; 1998; 5(1):52-63. PubMed ID: 9476967
[TBL] [Abstract][Full Text] [Related]
33. [p53: prospects for gene therapy of cancer].
Soddu S; Sacchi A
Clin Ter; 1998; 149(4):289-95. PubMed ID: 9866891
[TBL] [Abstract][Full Text] [Related]
34. Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate.
Guo H; Choudhury Y; Yang J; Chen C; Tay FC; Lim TM; Wang S
J Gene Med; 2011 Jan; 13(1):26-36. PubMed ID: 21259406
[TBL] [Abstract][Full Text] [Related]
35. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
36. Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53.
Logunov DY; Ilyinskaya GV; Cherenova LV; Verhovskaya LV; Shmarov MM; Chumakov PM; Kopnin BP; Naroditsky BS
Gene Ther; 2004 Jan; 11(1):79-84. PubMed ID: 14681700
[TBL] [Abstract][Full Text] [Related]
37. p53: balancing tumour suppression and implications for the clinic.
Buganim Y; Rotter V
Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
[TBL] [Abstract][Full Text] [Related]
38. DNA binding and selective gene induction by different forms of the p53 protein.
Mayelzadeh F; Martinez JD
Oncogene; 2007 May; 26(21):2955-63. PubMed ID: 17130840
[TBL] [Abstract][Full Text] [Related]
39. [Adenoviral p53 gene therapy for human lung cancer].
Fujiwara T; Tanaka N
Gan To Kagaku Ryoho; 2003 Apr; 30(4):460-7. PubMed ID: 12722675
[TBL] [Abstract][Full Text] [Related]
40. [P53 mutations, asset or disadvantage for cancer chemotherapy].
Jacquemin-Sablon A
Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
